MGNX - MacroGenics shares fall on early-stage MGC018 cancer safety data

MacroGenics shares fall ([[MGNX]] -5.7%) after the company posted preliminary safety and anti-tumor activity data from its ongoing Phase 1 clinical trial of MGC018.A total of 29 patients with advanced solid tumors were enrolled in five dose escalation cohorts with MGC018 at 0.5 to 4.0 mg/kg, administered intravenously every three weeks.In the dose escalation overall, at least one treatment-related adverse event was experienced by 93% of the patient ((27 of 29)).At 4.0 mg/kg, one patient developed a dose-limiting toxicity manifested by Grade 3 fatigue that lasted for more than 72 hours and as previously reported, a Grade 4 neutropenia occurred in a patient in the 2.0 mg/kg cohort, the company said.MGC018-related toxicities included hematologic and skin toxicities that have been clinically manageable.The company, however, highlighted that preliminary evidence of anti-tumor activity by MGC018 has been observed, most notably in patients with advanced metastatic castration-resistant prostate cancer ((mCRPC)).Reductions in prostate-specific antigen ((PSA))

For further details see:

MacroGenics shares fall on early-stage MGC018 cancer safety data